EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Influence of Cytogenetics on the Outcome of Patients With High‐Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide

Bengt Rasmussen iD, Lars Nilsson, Magnus Tobiasson, Martin Jädersten, Hege Garelius, Ingunn Dybedal, Kirsten Grønbaek, Elisabeth Ejerblad, Fryderyk Lorenz, Max Flogegård, Claus Werenberg Marcher, Lucia Cavalier und 8 weitere

Genes, Chromosomes and Cancer · 2025

DOI: 10.1002/gcc.70029 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Genes, Chromosomes and Cancer, 2025. Verfasst von Bengt Rasmussen und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Azacitidine, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Nordic Cancer Union, Cancerfonden, Celgene.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In myelodysplastic syndromes (MDS), cytogenetic characteristics of the malignant bone marrow cells influence the clinical course. The aim of this study was to evaluate whether cytogenetics is useful to predict outcome and response in patients with del(5q) under azacitidine (AZA) ± lenalidomide (LEN) therapy. We therefore performed comprehensive cytogenetic analyses in MDS patients with del(5q) treated within the randomized phase II trial NMDSG10B. Seventy‐two patients were enrolled in the study and 46 patients (64%) had sufficient cytogenetics at inclusion and response evaluation. Karyotyping was significantly more sensitive during follow‐up to detect del(5q) compared to FISH, 34 patients (97%) versus 27 patients (77%) ( p = 0.027). The overall response rate (ORR) did not differ between the 11 patients with < 3 aberrations (median 1 aberration) and the 59 patients with ≥ 3 aberrations (median 7 aberrations, range 3–16), while ≥ 3 aberrations were associated with shorter overall survival (OS), 9.9 months versus 25.2 months ( p = 0.004). OS was significantly shorter in patients with unbalanced translocation of 5q than patients with del (5)(q14q34), 8.4 months versus 21.1 months ( p = 0.004). Both complex karyotype and multi‐hit TP53 alterations were more frequent in patients with unbalanced translocations of 5q versus del (5)(q14q34), 98% and 88% versus 67% and 47% (each p = < 0.001). Most patients with cytogenetic progression had multi‐hit TP53 alterations at inclusion. Cytogenetic progression occurred at a similar frequency in the AZA arm and in the AZA + LEN arm. In summary, this study in homogenously treated MDS patients with different abnormalities of 5q demonstrates the influence of cytogenetics on treatment results. Trial Registration: EudraCT number: 2011‐001639‐21; ClinicalTrials.gov identifier: NCT01556477.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesAzacitidineAntineoplastic Combined Chemotherapy ProtocolsHumansLenalidomideMaleFemaleChromosomes, Human, Pair 5AgedChromosome DeletionMiddle AgedAged, 80 and overThalidomideAdultTreatment OutcomeCytogenetic Analysis

Stichwörter der Autor:innen

TP53azacitidinedeletion 5qhigh‐risk myelodysplastic syndromelenalidomideoutcome

Substanzen

LenalidomideAzacitidineThalidomide

Autor:innen und Institutionen

  • Division of Hematology, Department of Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
  • Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.
  • Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
  • Center for Hematology and Regenerative Medicine (HERM), Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Section of Hematology and Coagulation, Department of Specialist Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Department of Hematology, Oslo University Hospital, Oslo, Norway.

ORCID-Profile: Bengt Rasmussen

Förderung

  • Nordic Cancer Union
  • Cancerfonden
  • Celgene

Zitieren

APA

Rasmussen, B., Nilsson, L., Tobiasson, M., Jädersten, M., Garelius, H., Dybedal, I., Grønbaek, K., Ejerblad, E., Lorenz, F., Flogegård, M., Marcher, C. W., Cavalier, L., Ebeling, F., Olsnes, A. M., Nørgaard, J. M., Saft, L., Möllgård, L., Hellström-Lindberg, E., Schlegelberger, B., & Göhring, G. (2025). Influence of Cytogenetics on the Outcome of Patients With High‐Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide. Genes, Chromosomes and Cancer. https://doi.org/10.1002/gcc.70029

Vancouver

Rasmussen B, Nilsson L, Tobiasson M, Jädersten M, Garelius H, Dybedal I, et al. Influence of Cytogenetics on the Outcome of Patients With High‐Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide. Genes, Chromosomes and Cancer. 2025. doi:10.1002/gcc.70029

BibTeX
@article{Rasmussen2025,
  author = {Rasmussen, Bengt and Nilsson, Lars and Tobiasson, Magnus and Jädersten, Martin and Garelius, Hege and Dybedal, Ingunn and Grønbaek, Kirsten and Ejerblad, Elisabeth and Lorenz, Fryderyk and Flogegård, Max and Marcher, Claus Werenberg and Cavalier, Lucia and Ebeling, Freja and Olsnes, Astrid Marta and Nørgaard, Jan Maxwell and Saft, Leonie and Möllgård, Lars and Hellström-Lindberg, Eva and Schlegelberger, Brigitte and Göhring, Gudrun},
  title = {Influence of Cytogenetics on the Outcome of Patients With High‐Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide},
  journal = {Genes, Chromosomes and Cancer},
  year = {2025},
  doi = {10.1002/gcc.70029}
}
Kostenlos starten →